Tuberculosis-HIV treatment with Rifampicin or Rifabutin: are the outcomes different?

dc.creatorSchmaltz, Carolina Arana Stanis
dc.creatorDemitto, Fernanda de Oliveira
dc.creatorSant’Anna, Flavia Marinho
dc.creatorRolla, Valeria Cavalcanti
dc.date2019-03-18T13:13:14Z
dc.date2019-03-18T13:13:14Z
dc.date2019
dc.date.accessioned2023-09-27T00:01:04Z
dc.date.available2023-09-27T00:01:04Z
dc.identifierSCHMALTZ, Carolina Arana Stanis et al. Tuberculosis-HIV treatment with Rifampicin or Rifabutin: are the outcomes different? Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 114, p. 1-5, 2019.
dc.identifier0074-0276
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/32134
dc.identifier10.1590/0074-02760180420
dc.identifier1678-8060
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8896578
dc.descriptionBackground: Rifamycins are a group of antibiotics mainly used in the treatment of tuberculosis (TB), however they interactwith antiretroviral therapy (ART). Rifabutin allows more regimens options for concomitant imunodeficiency virus (HIV) treatment compared to rifampicin. Objective: Compare the outcomes of TB-HIV co-infected patients who used rifampicin or rifabutin. Methods: We analysed data from a prospective cohort study at National Institute of Infectious Diseases Evandro Chagas, Rio de Janeiro (RJ), Brazil. Patients who were treated for TB and HIV with rifampicin or rifabutin, from February 2011 to September 2016 were included. Findings: There were 130 TB-HIV patients, of whom 102 were treated with rifampicin and 28 with rifabutin. All patients in the rifabutin-treated group and 55% of the rifampicin-treated group patients were ART-experienced. Patients treated with rifampicin had similar abandon and cure rates, interruptions in treatment due to adverse reactions, immune reconstitution inflammatory syndrome and a similar mortality rate as those treated with rifabutin. However, rifampicin-treated patients had higher CD4 counts and more frequently undetectable HIV viral load by the end of treatment (67% versus 18%, p < 0.001) compared to rifabutin-treated patients, even when only ART-experienced patients were evaluated (66,6% versus 36,3%, p = 0.039). Conclusion: Patients who used rifabutin had worst immune and virological control. This group had more ART-experienced patients. New and simpler regimens are needed for patients who do not respond to previous antiretroviral therapies.
dc.formatapplication/pdf
dc.languageeng
dc.publisherInstituto Oswaldo Cruz
dc.rightsopen access
dc.subjectTuberculosis
dc.subjectHIV
dc.subjectRifampicin
dc.subjectRifabutin
dc.subjectRifamycin
dc.subjectOutcomes
dc.titleTuberculosis-HIV treatment with Rifampicin or Rifabutin: are the outcomes different?
dc.typeArticle


Este ítem pertenece a la siguiente institución